An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions

References

1. ↵
   Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR Am J Roentgenol 1995;164:1147–1152

   PubMed
2. ↵
   Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494–498

   PubMedWeb of Science
3. ↵
   Harisinghani MG, Barentsz J, Hahn PF, at al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491–2499

   CrossRefPubMedWeb of Science
4. ↵
   Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles Feridex and Combidex in imaging intracranial tumors. AJNR Am J Neuroradiol 2002;23:510–519

   Abstract/FREE Full Text
5. ↵
   Neuwelt EA, Varallyay P, Bago A, et al. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumors. Neuropathol Appl Neurobiol 2004;30:456–472

   CrossRefPubMedWeb of Science
6. ↵
   Neuwelt EA, Weissleder R, Nilaver G, et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 1994;34:777–784

   PubMedWeb of Science
7. ↵
   Schmitz SA, Taupitz M, Wagner S, et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:355–361

   CrossRefPubMedWeb of Science
8. ↵
   Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453–2458

   Abstract/FREE Full Text
9. ↵
   Neuwelt EA. Mechanisms of disease: the blood brain barrier. Neurosurgery 2004;54131–54142
10. ↵
    Jung C, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661–674

    CrossRefPubMedWeb of Science
11. ↵
    Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003;228:777–788

    PubMedWeb of Science
12. ↵
    McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301–307

    PubMedWeb of Science
13. ↵
    Corot C, Petry K, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004;39:619–625

    CrossRefPubMed
14. ↵
    Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;4:813–817
15. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53–62

    CrossRefPubMedWeb of Science
16. Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in subjects with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526–530

    Abstract/FREE Full Text
17. ↵
    Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229–235

    Abstract/FREE Full Text
18. ↵
    Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120:1149–1161

    Abstract/FREE Full Text
19. ↵
    Dousset V, Brochet B, Caille J, Petry K. Enhancement of multiple sclerosis lesions with ultra-small particle iron oxide. Proc Intl Soc Mag Reson Med 2001;9:261
20. ↵
    Rausch M, Hiestand P., Baumann D, et al. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003;50:309–314

    CrossRefPubMedWeb of Science
21. ↵
    Floris S, Blezer ELA, Schreibelt, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004;127:616–627

    Abstract/FREE Full Text
22. ↵
    Arbab AS, Yocum GT, Kalish H, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004;104:1217–1223

    Abstract/FREE Full Text
23. ↵
    Anderson SA, Shukaliak-Quandt J, Jordan EK, et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 2004;55:654–659

    CrossRefPubMedWeb of Science
24. ↵
    Elster AD. Magnetic resonance contrast enhancement in cerebral infarction. Neuroimaging Clin N Am 1994;4:89–100

    PubMed
25. Moseley ME, Kucharczyk J, Mintorovitch J, et al. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol 1990;11:423–429

    Abstract/FREE Full Text
26. ↵
    Reith W, Forsting M, Vogler H, et al. Early MR detection of experimentally induced cerebral ischemia using magnetic susceptibility contrast agents: comparison between gadopentetate dimeglumine and iron oxide particles. AJNR Am J Neuroradiol 1995;16:53–60

    Abstract
27. ↵
    Hunt MA, Bago AG, Neuwelt EA. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors using ferumoxtran-10. AJNR Am J Neuroradiol 2005;26:1084–1088

    Abstract/FREE Full Text
28. ↵
    Zhu J, Wu X, Zhang HL. Adult neural stem cell therapy: expansion in vitro, tracking in vivo and clinical transplantation. Curr Drug Targets 2005;6:97–110

    CrossRefPubMedWeb of Science
29. ↵
    Rooney WD, Telang FW, Springer-Verlag CS. Quantitative 4T determination of normal human brain vascular properties suggests CR transport across BBB. Proc Int Soc Magn Reson Med 2002;10:1314
30. Rooney W, Li X, Telang F, Taylor M, et al. First pass bolus-tracking measurement of transendothelial water exchange in healthy controls. Proc Int Soc Magn Reson Med 2004;12:1390
31. ↵
    Yankeelov TE, Rooney WD, Huang W, et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 2005;18:173–185

    CrossRefPubMedWeb of Science